SIK2 is altered in 1.12% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, and breast invasive lobular carcinoma having the greatest prevalence of alterations .
The most common alterations in SIK2 are SIK2 Amplification (0.29%), SIK2 A408V (0.04%), SIK2 A633V (0.04%), SIK2 A732T (0.04%), and SIK2 A854T (0.04%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.